Medication info
Duotelmi Plus Tablets 80/5/5 mg (Telmisartan, Amlodipine, Rosuvastatin)

Duotelmi Plus Tablets 80/5/5 mg (Telmisartan, Amlodipine, Rosuvastatin)

Prescription medicationTabletOral
Ingredient · strength
Telmisartan›80mg / 1 tabletAmlodipine Besylate›6.935mg / 1 tabletRosuvastatin Calcium›5.2mg / 1 tablet
Manufacturer / importer
HanKook Hutech Pharmaceutical Co., Ltd.
Appearance
Light pink oval film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202500426 · Approved 2025.02.26 · Insurance code 649106120

Summary

Main use
Treatment of hypertension and dyslipidemia, and prevention of atherosclerosis progression and cardiovascular disease risk
Who takes it
Adults
Adult dose
Take 1 tablet once daily with water, with or without food. If possible, it is recommended to take it at the same time each day (e.g., in the morning). This drug is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan/amlodipine combination and rosuvastatin. Patients receiving telmisartan/amlodipine in combination with rosuvastatin as a separate product may switch to this drug (a fixed-dose combination with the same amount of each active ingredient) for convenience. Before administering the telmisartan/amlodipine combination, it is recommended that the dose be adjusted using the individual components (amlodipine or telmisartan). However, if blood pressure is not controlled with the individual components, switching directly to the telmisartan/amlodipine combination may be considered as follows. - 40/5 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or telmisartan 40 milligrams. - 80/5 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or this drug 40/5 milligrams. - 40/10 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 10 milligrams. - 80/10 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 10 milligrams or this drug 40/10 milligrams. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. For patients with severe renal impairment, it is recommended to start treatment at a lower dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40 milligrams in patients with mild or moderate hepatic impairment. Older adults: In patients aged 75 years and older, amlodipine clearance is reduced; therefore, start treatment at a lower dose and increase the dose gradually. Primary hypercholesterolemia (including heterozygous familial hypercholesterolemia, type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia: Patients receiving rosuvastatin should follow a standard cholesterol-lowering diet before and during treatment and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or more, based on LDL cholesterol levels, treatment goals, and patient response; it may be increased to a maximum of 20 milligrams once daily. Older adults: No dose adjustment is necessary. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Special care should be taken when administering rosuvastatin 20mg to patients with moderate renal impairment. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. Race: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of rosuvastatin 40 milligrams is contraindicated in some of these patients.

Ingredients

Manufacturer
HanKook Hutech Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension and dyslipidemia, and prevention of atherosclerosis progression and cardiovascular disease risk

  • Essential hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol levels
  • smoking
  • family history of early coronary heart disease
View approved original text

This medication is used for patients with essential hypertension whose blood pressure is not adequately controlled even with the combination of telmisartan and amlodipine. Furthermore, rosuvastatin is used as an adjunct therapy for patients with primary hypercholesterolemia or mixed dyslipidemia that are not controlled by diet and exercise alone. Rosuvastatin particularly lowers total cholesterol and LDL levels in patients with hypercholesterolemia, delaying the progression of atherosclerosis, and is also helpful in treating patients with homozygous familial hypercholesterolemia and dysbetalipoproteinemia. Additionally, it contributes to reducing the risk of stroke, myocardial infarction, and postoperative vascular reintervention in adults with a high risk of cardiovascular disease. This medication improves cardiovascular health by managing both hypertension and dyslipidemia simultaneously.

How to take

Adult dose

Take 1 tablet once daily with water, with or without food. If possible, it is recommended to take it at the same time each day (e.g., in the morning). This drug is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan/amlodipine combination and rosuvastatin. Patients receiving telmisartan/amlodipine in combination with rosuvastatin as a separate product may switch to this drug (a fixed-dose combination with the same amount of each active ingredient) for convenience. Before administering the telmisartan/amlodipine combination, it is recommended that the dose be adjusted using the individual components (amlodipine or telmisartan). However, if blood pressure is not controlled with the individual components, switching directly to the telmisartan/amlodipine combination may be considered as follows. - 40/5 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or telmisartan 40 milligrams. - 80/5 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or this drug 40/5 milligrams. - 40/10 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 10 milligrams. - 80/10 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 10 milligrams or this drug 40/10 milligrams. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. For patients with severe renal impairment, it is recommended to start treatment at a lower dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40 milligrams in patients with mild or moderate hepatic impairment. Older adults: In patients aged 75 years and older, amlodipine clearance is reduced; therefore, start treatment at a lower dose and increase the dose gradually. Primary hypercholesterolemia (including heterozygous familial hypercholesterolemia, type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia: Patients receiving rosuvastatin should follow a standard cholesterol-lowering diet before and during treatment and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or more, based on LDL cholesterol levels, treatment goals, and patient response; it may be increased to a maximum of 20 milligrams once daily. Older adults: No dose adjustment is necessary. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Special care should be taken when administering rosuvastatin 20mg to patients with moderate renal impairment. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. Race: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of rosuvastatin 40 milligrams is contraindicated in some of these patients.

Precautions

This medication may cause serious harm to the fetus and newborn if taken during pregnancy; therefore, it should be discontinued immediately upon confirmation of pregnancy. Patients who are allergic to any components of this medication or similar drugs, or those with certain hereditary conditions should not take it. Patients with severely impaired liver or kidney function, certain heart conditions, or a history of angioedema should also avoid this medication. Elderly patients or those with significantly low blood pressure, mildly impaired liver function, and patients at risk of muscle-related conditions should use this medication with caution. This medication may cause muscle-related side effects such as myalgia or muscle weakness, and if these symptoms occur, the patient should consult a physician immediately. Regular liver function tests are necessary as this medication may lead to liver function abnormalities, and if liver enzyme levels increase significantly, discontinuation of the drug is warranted. This medication may interact with other drugs; therefore, it is essential to inform the physician or pharmacist of any other medications currently being taken. Breastfeeding women are advised not to take this medication; if unavoidable, breastfeeding should be discontinued. Safety and efficacy in children and adolescents have not been sufficiently confirmed, and use is not recommended. In case of overdose, symptoms such as decreased blood pressure, dizziness, and irregular heartbeat may occur, and immediate medical attention is required. This medication should be kept out of reach of children and not transferred to other containers for safety.

Side effects

Viral upper respiratory tract infection, dyspnea, rectal bleeding, dyspepsia, atopic dermatitis, peripheral edema, chronic gastritis, various gastrointestinal disorders, hiatal hernia, dysuria, rhinitis, oropharyngeal discomfort, pulmonary disease, unspecified intestinal disease, benign gastrointestinal neoplasm, hemorrhoids, skeletal pain, osteoporosis, sensory impairment, movement disorders, frequent urination, tinnitus, hearing loss, halitosis, fatty liver, upper respiratory infection, low back pain, sinusitis, diarrhea, pharyngitis, influenza-like symptoms, dyspepsia, myalgia, urinary tract infection, abdominal pain, headache, dizziness, pain, fatigue, cough, hypertension, chest pain, nausea, palpitations, dependent edema, angina pectoris, rapid pulse, leg edema, abnormal ECG, insomnia, drowsiness, migraine, vertigo, sensory disturbances, involuntary muscle contraction, erectile dysfunction, increased sweating, flushing, allergy, fever, leg pain, malaise, palpitations, angioedema, angioedema, erythema multiforme, pruritus, rash, erythematous rash, papular rash, frequent urination, cystitis, leukopenia, purpura, thrombocytopenia, vascular disease, cerebrovascular disease, visual disturbances, conjunctivitis, ear pain, weakness, constipation, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, headache, dizziness, constipation, nausea, abdominal pain, arrhythmia, bradycardia, chest pain, peripheral ischemia, syncope, postural hypotension, vasculitis, peripheral neuropathy, tremor, anorexia, dysphagia, vomiting, gingival hyperplasia, allergic reaction, low back pain, burning sensation, malaise, rigidity, weight gain, weight loss, arthralgia, arthritis, muscle cramps, myalgia, sexual dysfunction, insomnia, neurogenic pain, depression, abnormal dreams, anxiety, depersonalization, dyspnea, epistaxis, angioedema, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, memory loss, weakness, frailty, facial edema, lower extremity edema, thrombocytopenia, increased uric acid, abnormal liver function, acute renal failure, anaphylactic reaction, tendon pain, muscle cramps, joint pain, fatigue, numbness, sensory disturbances, chest discomfort, anorexia, abdominal distension, syncope, generalized pain, gout, erectile dysfunction

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light and should be stored in a container that does not allow light to enter. It is best kept at room temperature, between 1 and 30 degrees Celsius. Proper storage conditions will help maintain the drug's efficacy.

Appearance and packaging

Appearance

Light pink oval film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.